Vector integration is nonrandom and clustered and influences the fate of lymphopoiesis in SCID-X1 gene therapy
- PMID: 17671652
- PMCID: PMC1934585
- DOI: 10.1172/JCI31659
Vector integration is nonrandom and clustered and influences the fate of lymphopoiesis in SCID-X1 gene therapy
Abstract
Recent reports have challenged the notion that retroviruses and retroviral vectors integrate randomly into the host genome. These reports pointed to a strong bias toward integration in and near gene coding regions and, for gammaretroviral vectors, around transcription start sites. Here, we report the results obtained from a large-scale mapping of 572 retroviral integration sites (RISs) isolated from cells of 9 patients with X-linked SCID (SCID-X1) treated with a retrovirus-based gene therapy protocol. Our data showed that two-thirds of insertions occurred in or very near to genes, of which more than half were highly expressed in CD34(+) progenitor cells. Strikingly, one-fourth of all integrations were clustered as common integration sites (CISs). The highly significant incidence of CISs in circulating T cells and the nature of their locations indicate that insertion in many gene loci has an influence on cell engraftment, survival, and proliferation. Beyond the observed cases of insertional mutagenesis in 3 patients, these data help to elucidate the relationship between vector insertion and long-term in vivo selection of transduced cells in human patients with SCID-X1.
Figures
Comment in
-
Retroviral integration and human gene therapy.J Clin Invest. 2007 Aug;117(8):2083-6. doi: 10.1172/JCI32949. J Clin Invest. 2007. PMID: 17671645 Free PMC article.
Similar articles
-
Retroviral integration and human gene therapy.J Clin Invest. 2007 Aug;117(8):2083-6. doi: 10.1172/JCI32949. J Clin Invest. 2007. PMID: 17671645 Free PMC article.
-
Gammaretrovirus-mediated correction of SCID-X1 is associated with skewed vector integration site distribution in vivo.J Clin Invest. 2007 Aug;117(8):2241-9. doi: 10.1172/JCI31661. J Clin Invest. 2007. PMID: 17671654 Free PMC article. Clinical Trial.
-
Dynamics of gene-modified progenitor cells analyzed by tracking retroviral integration sites in a human SCID-X1 gene therapy trial.Blood. 2010 Jun 3;115(22):4356-66. doi: 10.1182/blood-2009-12-257352. Epub 2010 Mar 12. Blood. 2010. PMID: 20228274 Free PMC article. Clinical Trial.
-
Gene Therapy for X-Linked Severe Combined Immunodeficiency: Where Do We Stand?Hum Gene Ther. 2016 Feb;27(2):108-16. doi: 10.1089/hum.2015.137. Hum Gene Ther. 2016. PMID: 26790362 Free PMC article. Review.
-
Stem cell gene transfer: insights into integration and hematopoiesis from primate genetic marking studies.Ann N Y Acad Sci. 2005 Jun;1044:178-82. doi: 10.1196/annals.1349.023. Ann N Y Acad Sci. 2005. PMID: 15958711 Review.
Cited by
-
Mouse transplant models for evaluating the oncogenic risk of a self-inactivating XSCID lentiviral vector.PLoS One. 2013 Apr 23;8(4):e62333. doi: 10.1371/journal.pone.0062333. Print 2013. PLoS One. 2013. PMID: 23626802 Free PMC article.
-
Towards a Safer, More Randomized Lentiviral Vector Integration Profile Exploring Artificial LEDGF Chimeras.PLoS One. 2016 Oct 27;11(10):e0164167. doi: 10.1371/journal.pone.0164167. eCollection 2016. PLoS One. 2016. PMID: 27788138 Free PMC article.
-
The balance between the intronic miR-342 and its host gene Evl determines hematopoietic cell fate decision.Leukemia. 2021 Oct;35(10):2948-2963. doi: 10.1038/s41375-021-01267-5. Epub 2021 May 21. Leukemia. 2021. PMID: 34021250 Free PMC article.
-
Retroviral integration and human gene therapy.J Clin Invest. 2007 Aug;117(8):2083-6. doi: 10.1172/JCI32949. J Clin Invest. 2007. PMID: 17671645 Free PMC article.
-
A transposon and transposase system for human application.Mol Ther. 2010 Apr;18(4):674-83. doi: 10.1038/mt.2010.2. Epub 2010 Jan 26. Mol Ther. 2010. PMID: 20104209 Free PMC article. Review.
References
-
- Cavazzana-Calvo M., et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science. 2000;288:669–672. - PubMed
-
- Aiuti A., et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science. 2002;296:2410–2413. - PubMed
-
- Gaspar H.B., et al. Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet. 2004;364:2181–2187. - PubMed
-
- Coffin, J.M., Hughes, S.H., and Varmus, H.E. 1997.Retroviruses . Cold Spring Harbor Laboratory Press. Plainview, New York, USA. 843 pp. - PubMed
-
- Moolten F.L., Cupples L.A. A model for predicting the risk of cancer consequent to retroviral gene therapy. Hum. Gene Ther. 1992;3:479–486. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical